Literature DB >> 16699676

[Ophthalmological alterations in outpatients with systemic lupus erythematosus].

Tatiana Klejnberg1, Haroldo Vieira de Moraes Junior.   

Abstract

PURPOSE: To evaluate the ophthalmological alterations in patients with systemic lupus erythematosus (SLE).
METHODS: A descriptive cross-sectional study was conducted to analyze 70 patients with diagnosis of SLE based on the American College of Rheumatology criteria. Data regarding sex, age, ethnicity, duration of disease, disease activity, use of corticosteroids and antimalarial drugs, and presence of ophthalmological symptoms were recorded and a full ophthalmic examination was carried out.
RESULTS: Sixty-two patients (88.6%) were females, 43 patients (61.4%) were white. Mean age was 43.9 years, 57 patients (81.4%) presented no sign of active disease and 46 patients (65.7%) had no ophthalmological complaints. Dry eye syndrome was diagnosed in 22 patients (31.4%), bilateral subcapsular cataract in 15 patients (21.1%) and glaucoma in 2 patients (2.9%). Fundoscopic evaluation disclosed 8 patients (11.4%) with drusen, 7 (10.0%) with RPE atrophy, 2 patients (2.9%) presented pathological disc excavation, 2 (2.9%) vascular tortuosity and arteriovenous crossing changes, 1 patient (1.4%) had macular chorioretinitis scar and 1 patient (1.4%) had branch retinal vein occlusion.
CONCLUSION: SLE is a disease that can present with ophthalmic involvement, usually benign in outpatients. Dry eye and cataract are the commonest ocular findings. The former seems to be more related to SLE itself while the latter probably relates to the chronic use of corticosteroids for the disease treatment. Antimalarial drugs do not frequently cause ophthalmic lesions, although further studies must be conducted in order to assess their impact on patients' long-term visual quality. In the patients with the disease under control, ocular damage is more related to systemic treatment what enhances the need for ophthalmological examination as a routine even in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699676     DOI: 10.1590/s0004-27492006000200018

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  3 in total

1.  Risk factors for cataracts in systemic lupus erythematosus (SLE).

Authors:  Khaled Alderaan; Vuk Sekicki; Laurence S Magder; Michelle Petri
Journal:  Rheumatol Int       Date:  2014-09-26       Impact factor: 2.631

2.  Fcγ receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration.

Authors:  Salome Murinello; Robert F Mullins; Andrew J Lotery; V Hugh Perry; Jessica L Teeling
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-13       Impact factor: 4.799

Review 3.  Gender and ocular manifestations of connective tissue diseases and systemic vasculitides.

Authors:  Maria M Choudhary; Rula A Hajj-Ali; Careen Y Lowder
Journal:  J Ophthalmol       Date:  2014-03-17       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.